Efficient medical treatment for Medulloblastoma in India available at best hospitals

Published: 18th February 2010
Views: N/A

Treatment for Medulloblastoma in India is done at best neurosurgical institute. Indian medical tourism offers our clients the excellent range of medical treatments, with extremely competent, highly respected Indian medical specialists. India boasts of several good private owned hospitals in Mumbai, Delhi, Hyderabad and Chennai with facilities second to none. They have some of the best specialist doctors, with most top end being educated in USA and UK. People prefer treatment for Medulloblastoma in India because it is available at various hospitals where the surgeon and there team are dedicated to bring smile on there patience face.

What is Medulloblastoma?

Medulloblastoma is a malignant, invasive embryonal tumor of the cerebellum which occurs more often in children. It has a predominantly neuronal differentiation and a tendency to metastasize via CSF pathways. Histologically, classic Medulloblastomas are composed of densely packed cells with round-to-oval or carrot-shaped highly hyperchromatic nuclei surrounded by scanty cytoplasm. Neuroblastic rosettes are a typical but not constant feature. There are four histologic types: Desmoplastic Medulloblastoma, Large Cell Medulloblastoma, Medullomyoblastoma, Melanotic Medulloblastoma.

Symptoms of Medulloblastoma

The list of signs and symptoms mentioned in various sources for Medulloblastoma includes the symptoms listed below:

• Increased intracranial pressure

• Brain tumor

• Brain swelling

• Obstruction of cerebrospinal fluid flow

• Enlarged head

• Vomiting

• Nausea

• Irritability

• Lethargy

• Personality changes

• Attention deficit

• Loss of motor skills

• Impaired walking ability

• Impaired speech

• Impaired ability to control voluntary movements

• Ataxic gait

• Muscle weakness

Treatment options for Medulloblstoma

Standard therapy for Medulloblastoma consists of aggressive surgery followed by radiation to the entire craniospinal axis with boost to both the primary tumor site and focal CNS metastatic sites. Recently, adjuvant chemotherapy has also been shown to be beneficial.

• Radiation therapy

o Average-risk disease

 Reducing the amount of craniospinal radiation in an attempt to decrease morbidity without jeopardizing survival appears to be successful in this group. In a report by the International Society of Pediatric Oncology, children with average-risk medulloblastoma randomly received either the standard 36 Gy or a reduced dose of 24 Gy to the neuraxis. It was found that no statistical difference in progression-free survival rates was demonstrated between the groups as long as the initiation of radiotherapy was not delayed by the administration of chemotherapy before radiation.

• Chemotherapy

o Average-risk disease

 The most encouraging results with adjuvant chemotherapy have been reported in children with nondisseminated medulloblastoma receiving 8 cycles of lomustine (CCNU), vincristine and cisplatin chemotherapy for approximately 1 year following conventional dose radiotherapy and concomitant vincristine.

Surgical Care

• Suboccipital craniotomy

o Because the tumor is often friable, gentle suction is used. Microdissection is used to remove adherent portions.

o Modern neurosurgical techniques permit complete or near-complete resection with little or no significant increase in morbidity and mortality rates compared with more conservative surgery.

o Because surgical estimates of the extent of resection may not be reliable, postoperative MRI evaluation for residual disease is required within several days of the procedure.

o As many as 40% of patients have some degree of new neurologic dysfunction postoperatively. One ill-defined syndrome is posterior fossa syndrome, characterized by mutism, cerebellar dysfunction, supranuclear cranial nerve palsy and hemiparesis that occur 12-48 hours after surgery. As many as 50% of patients have residual deficits.

• Ventriculoperitoneal shunt: Approximately 50% of patients require placement of a ventriculoperitoneal shunt at the time of operation (or shortly thereafter) because of unresolving obstructive hydrocephaly. Third ventriculostomy is increasingly used to avoid the placement of a permanent ventricular shunt.

Follow up care for Medulloblastoma

Inpatient & Outpatient Medications for Medulloblastoma

• Inpatient medications are dictated by the most current chemotherapeutic protocols available for the treatment of medulloblastoma. The most commonly used chemotherapeutic agents are DNA alkylators.

• Most regimens require the concomitant use of an antiemetic.

• Because of the immunosuppressive effects of chemotherapy, trimethoprim sulfamethoxazole and nystatin are commonly prescribed for prophylaxis against Pneumocystis carinii pneumonia and mucocutaneous candidiasis, respectively, for the duration of treatment.

• Granulocyte colony stimulating factor (GCSF) following chemotherapy may be used in treatment regimens expected to cause marked neutropenia.

Why India?

Many hospitals in India are internationally accredited for the treatment of Medulloblastoma in India. Medical tourism combines the health and holiday aspects together, to offer you great savings in time and money. Hospitals of Delhi, Chennai, Mumbai offers world-class facilities for international patients. Goa is the famous tranquil beach paradise on the west coast of India and Mumbai is famous for its best hospitals which are equipped with the latest technical gadgets. Medical care tourism provides you both best treatment and quality, so you can get medical treatment and relax. For more details on Medulloblastoma in India, visit us at; http://www.forerunnershealthcare.com or you can mail us your queries at enquiry@forerunnershealthcare.com or you can contact us at +91-9371136499, +91-9860755000.

Report this article Ask About This Article

More to Explore